261 results on '"Hassanein, A."'
Search Results
2. SAT-082 A phase 2 study of OCE-205, a novel, selective vasopressin receptor mixed agonist-antagonist: positive proof-of-concept established in subjects with cirrhosis and hepatorenal syndromeacute kidney injury (HRS-AKI)
3. WED-294 The use of the FibroScan-AST score and AST to pre-identify metabolic dysfunction-associated steatohepatitis patients with active fibrogenesis in a Phase 1b open-label clinical trial
4. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
5. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
6. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
7. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
8. Velacur ACE outperforms CAP for liver fat quantification using MRI PDFF as the gold standard
9. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
10. EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients
11. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B
12. The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH
13. Efficacy and safety of leronlimab in patients with non-alcoholic steatohepatitis: topline results of NASH01 clinical trial
14. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
15. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
16. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B
17. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
18. A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure
19. EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients
20. Efficacy and safety of leronlimab in patients with non-alcoholic steatohepatitis: topline results of NASH01 clinical trial
21. A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure
22. SAT-432 - Velacur ACE outperforms CAP for liver fat quantification using MRI PDFF as the gold standard
23. Addition of palliative care nurse on the liver care team
24. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
25. Liver incytes: assessment of fibrosis and steatosis in patients and healthy volunteers
26. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
27. Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection
28. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
29. Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study
30. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
31. Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
32. Liver incytes: assessment of fibrosis and steatosis in patients and healthy volunteers
33. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C
34. Management of the patient with SVR
35. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
36. Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection
37. Addition of palliative care nurse on the liver care team
38. FRI-407-Elevating liver disease management in Egypt: A Project Echo® experience
39. LBP-24-Safety, tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with nonalcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study
40. FRI-414-The impact of self and parental perception of body image on management in patients with NAFLD
41. THU-272-A study investigating the effect of extracorporeal cellular therapy with C3A cells on the survival of alcoholic hepatitis designed along the guidelines of the NIAAA
42. FRI-058-Randomized controlled trial to compare efficacy of albumin dialysis using MARS versus new adsorbent recirculation for pruritus treatment
43. FRI-414-The impact of self and parental perception of body image on management in patients with NAFLD
44. FRI-413-Integrating nurses in the management and care of patients with NAFLD: Better adherence and outcomes
45. LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
46. FRI-407-Elevating liver disease management in Egypt: A Project Echo® experience
47. LBP-24-Safety, tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with nonalcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study
48. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection
49. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure
50. Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.